TNNT2 and cancer: Considering the 5-year survival after the timepoint of catherization, all parameters—including CAD, LVEF, hs-cTnT and NT-proBNP—were able to distinguish between patients with high and low survival rates in the total cancer as well as in the non-cancer cohort.